663 related articles for article (PubMed ID: 17194199)
1. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants.
Deming D; Sheahan T; Heise M; Yount B; Davis N; Sims A; Suthar M; Harkema J; Whitmore A; Pickles R; West A; Donaldson E; Curtis K; Johnston R; Baric R
PLoS Med; 2006 Dec; 3(12):e525. PubMed ID: 17194199
[TBL] [Abstract][Full Text] [Related]
2. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus.
Sheahan T; Whitmore A; Long K; Ferris M; Rockx B; Funkhouser W; Donaldson E; Gralinski L; Collier M; Heise M; Davis N; Johnston R; Baric RS
J Virol; 2011 Jan; 85(1):217-30. PubMed ID: 20980507
[TBL] [Abstract][Full Text] [Related]
3. Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform.
Agnihothram S; Menachery VD; Yount BL; Lindesmith LC; Scobey T; Whitmore A; Schäfer A; Heise MT; Baric RS
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540599
[TBL] [Abstract][Full Text] [Related]
4. Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice.
Rockx B; Sheahan T; Donaldson E; Harkema J; Sims A; Heise M; Pickles R; Cameron M; Kelvin D; Baric R
J Virol; 2007 Jul; 81(14):7410-23. PubMed ID: 17507479
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.
Rockx B; Corti D; Donaldson E; Sheahan T; Stadler K; Lanzavecchia A; Baric R
J Virol; 2008 Apr; 82(7):3220-35. PubMed ID: 18199635
[TBL] [Abstract][Full Text] [Related]
6. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.
Bolles M; Deming D; Long K; Agnihothram S; Whitmore A; Ferris M; Funkhouser W; Gralinski L; Totura A; Heise M; Baric RS
J Virol; 2011 Dec; 85(23):12201-15. PubMed ID: 21937658
[TBL] [Abstract][Full Text] [Related]
7. A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant.
Agnihothram S; Yount BL; Donaldson EF; Huynh J; Menachery VD; Gralinski LE; Graham RL; Becker MM; Tomar S; Scobey TD; Osswald HL; Whitmore A; Gopal R; Ghosh AK; Mesecar A; Zambon M; Heise M; Denison MR; Baric RS
mBio; 2014 Mar; 5(2):e00047-14. PubMed ID: 24667706
[TBL] [Abstract][Full Text] [Related]
8. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies.
Faber M; Lamirande EW; Roberts A; Rice AB; Koprowski H; Dietzschold B; Schnell MJ
J Gen Virol; 2005 May; 86(Pt 5):1435-1440. PubMed ID: 15831955
[TBL] [Abstract][Full Text] [Related]
9. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
Pushko P; Parker M; Ludwig GV; Davis NL; Johnston RE; Smith JF
Virology; 1997 Dec; 239(2):389-401. PubMed ID: 9434729
[TBL] [Abstract][Full Text] [Related]
10. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
[TBL] [Abstract][Full Text] [Related]
12. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y
Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615
[TBL] [Abstract][Full Text] [Related]
13. Pathways of cross-species transmission of synthetically reconstructed zoonotic severe acute respiratory syndrome coronavirus.
Sheahan T; Rockx B; Donaldson E; Corti D; Baric R
J Virol; 2008 Sep; 82(17):8721-32. PubMed ID: 18579604
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
15. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.
Tseng CT; Sbrana E; Iwata-Yoshikawa N; Newman PC; Garron T; Atmar RL; Peters CJ; Couch RB
PLoS One; 2012; 7(4):e35421. PubMed ID: 22536382
[TBL] [Abstract][Full Text] [Related]
16. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice.
Martinez DR; Schäfer A; Leist SR; De la Cruz G; West A; Atochina-Vasserman EN; Lindesmith LC; Pardi N; Parks R; Barr M; Li D; Yount B; Saunders KO; Weissman D; Haynes BF; Montgomery SA; Baric RS
Science; 2021 Aug; 373(6558):991-998. PubMed ID: 34214046
[TBL] [Abstract][Full Text] [Related]
17. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
Buchholz UJ; Bukreyev A; Yang L; Lamirande EW; Murphy BR; Subbarao K; Collins PL
Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9804-9. PubMed ID: 15210961
[TBL] [Abstract][Full Text] [Related]
18. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.
Du L; Zhao G; Chan CC; Sun S; Chen M; Liu Z; Guo H; He Y; Zhou Y; Zheng BJ; Jiang S
Virology; 2009 Oct; 393(1):144-50. PubMed ID: 19683779
[TBL] [Abstract][Full Text] [Related]
19. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice.
Lee JS; Groebner JL; Hadjipanayis AG; Negley DL; Schmaljohn AL; Welkos SL; Smith LA; Smith JF
Vaccine; 2006 Nov; 24(47-48):6886-92. PubMed ID: 16828936
[TBL] [Abstract][Full Text] [Related]
20. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein.
Fett C; DeDiego ML; Regla-Nava JA; Enjuanes L; Perlman S
J Virol; 2013 Jun; 87(12):6551-9. PubMed ID: 23576515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
